Cargando…

Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA

The adult attention-deficit/hyperactivity disorder (ADHD) quality-of-life (AAQoL) scale was previously validated in adult patients in the USA; here, the AAQoL is validated in adult European patients. Data from a 12-week open-label acute treatment period with atomoxetine (80–100 mg/day) in adults wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Brod, Meryl, Adler, Lenard A., Lipsius, Sarah, Tanaka, Yoko, Heinloth, Alexandra N., Upadhyaya, Himanshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449381/
https://www.ncbi.nlm.nih.gov/pubmed/25563210
http://dx.doi.org/10.1007/s12402-014-0160-z
_version_ 1782373843379159040
author Brod, Meryl
Adler, Lenard A.
Lipsius, Sarah
Tanaka, Yoko
Heinloth, Alexandra N.
Upadhyaya, Himanshu
author_facet Brod, Meryl
Adler, Lenard A.
Lipsius, Sarah
Tanaka, Yoko
Heinloth, Alexandra N.
Upadhyaya, Himanshu
author_sort Brod, Meryl
collection PubMed
description The adult attention-deficit/hyperactivity disorder (ADHD) quality-of-life (AAQoL) scale was previously validated in adult patients in the USA; here, the AAQoL is validated in adult European patients. Data from a 12-week open-label acute treatment period with atomoxetine (80–100 mg/day) in adults with ADHD were used. Patients (≥18 to ≤50 years old) had a score ≥2 on ≥6 items on the inattentive or hyperactive core subscales of Conners’ Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV); a CAARS-Inv:SV 18-item total ADHD symptom score ≥20; and Conners’ Adult ADHD Rating Scale-Observer: Screening Version 6-item inattentive or hyperactive core subscale scores ≥2. Data were stratified based on patients’ geographic region (Europe vs USA). Scale validation psychometric properties results were very similar between European (n = 1,217; 57.7 % male; mean age 33.0 years) and US (n = 602; 62.1 % male; mean age 33.5 years) patients, including factor loading, internal consistency, convergent and discriminant validity, and responsiveness. Exploratory factor analysis confirmed four AAQoL subscales. Internal consistency was acceptable (Cronbach’s alpha > 0.70 for all subscales). The AAQoL total score showed moderate convergent validity with CAARS-Inv:SV 18-item total ADHD symptom and clinical global impression-ADHD-severity (CGI-ADHD-S) scores; and strong convergent validity with Behavior Rating Inventory of Executive Function—Adult Version: Self-Report Global-Executive-Composite Index scores. Mean AAQoL total scores were significantly different among patients grouped by CGI-ADHD-S scores, suggesting good discriminant validity. The AAQoL total and subscale scores presented good responsiveness from baseline to 12 weeks. The AAQoL scale shows comparable validity in European and US adults with ADHD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12402-014-0160-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4449381
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-44493812015-06-04 Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA Brod, Meryl Adler, Lenard A. Lipsius, Sarah Tanaka, Yoko Heinloth, Alexandra N. Upadhyaya, Himanshu Atten Defic Hyperact Disord Original Article The adult attention-deficit/hyperactivity disorder (ADHD) quality-of-life (AAQoL) scale was previously validated in adult patients in the USA; here, the AAQoL is validated in adult European patients. Data from a 12-week open-label acute treatment period with atomoxetine (80–100 mg/day) in adults with ADHD were used. Patients (≥18 to ≤50 years old) had a score ≥2 on ≥6 items on the inattentive or hyperactive core subscales of Conners’ Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV); a CAARS-Inv:SV 18-item total ADHD symptom score ≥20; and Conners’ Adult ADHD Rating Scale-Observer: Screening Version 6-item inattentive or hyperactive core subscale scores ≥2. Data were stratified based on patients’ geographic region (Europe vs USA). Scale validation psychometric properties results were very similar between European (n = 1,217; 57.7 % male; mean age 33.0 years) and US (n = 602; 62.1 % male; mean age 33.5 years) patients, including factor loading, internal consistency, convergent and discriminant validity, and responsiveness. Exploratory factor analysis confirmed four AAQoL subscales. Internal consistency was acceptable (Cronbach’s alpha > 0.70 for all subscales). The AAQoL total score showed moderate convergent validity with CAARS-Inv:SV 18-item total ADHD symptom and clinical global impression-ADHD-severity (CGI-ADHD-S) scores; and strong convergent validity with Behavior Rating Inventory of Executive Function—Adult Version: Self-Report Global-Executive-Composite Index scores. Mean AAQoL total scores were significantly different among patients grouped by CGI-ADHD-S scores, suggesting good discriminant validity. The AAQoL total and subscale scores presented good responsiveness from baseline to 12 weeks. The AAQoL scale shows comparable validity in European and US adults with ADHD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12402-014-0160-z) contains supplementary material, which is available to authorized users. Springer Vienna 2015-01-07 2015 /pmc/articles/PMC4449381/ /pubmed/25563210 http://dx.doi.org/10.1007/s12402-014-0160-z Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Brod, Meryl
Adler, Lenard A.
Lipsius, Sarah
Tanaka, Yoko
Heinloth, Alexandra N.
Upadhyaya, Himanshu
Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA
title Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA
title_full Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA
title_fullStr Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA
title_full_unstemmed Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA
title_short Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA
title_sort validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in european patients: comparison with patients from the usa
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449381/
https://www.ncbi.nlm.nih.gov/pubmed/25563210
http://dx.doi.org/10.1007/s12402-014-0160-z
work_keys_str_mv AT brodmeryl validationoftheadultattentiondeficithyperactivitydisorderqualityoflifescaleineuropeanpatientscomparisonwithpatientsfromtheusa
AT adlerlenarda validationoftheadultattentiondeficithyperactivitydisorderqualityoflifescaleineuropeanpatientscomparisonwithpatientsfromtheusa
AT lipsiussarah validationoftheadultattentiondeficithyperactivitydisorderqualityoflifescaleineuropeanpatientscomparisonwithpatientsfromtheusa
AT tanakayoko validationoftheadultattentiondeficithyperactivitydisorderqualityoflifescaleineuropeanpatientscomparisonwithpatientsfromtheusa
AT heinlothalexandran validationoftheadultattentiondeficithyperactivitydisorderqualityoflifescaleineuropeanpatientscomparisonwithpatientsfromtheusa
AT upadhyayahimanshu validationoftheadultattentiondeficithyperactivitydisorderqualityoflifescaleineuropeanpatientscomparisonwithpatientsfromtheusa